These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 37637207)

  • 21. A bispecific antibody AP203 targeting PD-L1 and CD137 exerts potent antitumor activity without toxicity.
    Huang PL; Kan HT; Hsu CH; Hsieh HT; Cheng WC; Huang RY; You JJ
    J Transl Med; 2023 May; 21(1):346. PubMed ID: 37226226
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Targeting CXCR4 potentiates anti-PD-1 efficacy modifying the tumor microenvironment and inhibiting neoplastic PD-1.
    D'Alterio C; Buoncervello M; Ieranò C; Napolitano M; Portella L; Rea G; Barbieri A; Luciano A; Scognamiglio G; Tatangelo F; Anniciello AM; Monaco M; Cavalcanti E; Maiolino P; Romagnoli G; Arra C; Botti G; Gabriele L; Scala S
    J Exp Clin Cancer Res; 2019 Oct; 38(1):432. PubMed ID: 31661001
    [TBL] [Abstract][Full Text] [Related]  

  • 23. IL-15/IL-15Rα Heterodimeric Complex as Cancer Immunotherapy in Murine Breast Cancer Models.
    Guo S; Smeltz RB; Nanajian A; Heller R
    Front Immunol; 2020; 11():614667. PubMed ID: 33628206
    [TBL] [Abstract][Full Text] [Related]  

  • 24. High baseline tumor burden-associated macrophages promote an immunosuppressive microenvironment and reduce the efficacy of immune checkpoint inhibitors through the IGFBP2-STAT3-PD-L1 pathway.
    Wen Z; Sun H; Zhang Z; Zheng Y; Zheng S; Bin J; Liao Y; Shi M; Zhou R; Liao W
    Cancer Commun (Lond); 2023 May; 43(5):562-581. PubMed ID: 37031362
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Intratumoral IL-12 and TNF-alpha-loaded microspheres lead to regression of breast cancer and systemic antitumor immunity.
    Sabel MS; Skitzki J; Stoolman L; Egilmez NK; Mathiowitz E; Bailey N; Chang WJ; Chang AE
    Ann Surg Oncol; 2004 Feb; 11(2):147-56. PubMed ID: 14761917
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Enhanced efficacy and limited systemic cytokine exposure with membrane-anchored interleukin-12 T-cell therapy in murine tumor models.
    Zhang L; Davies JS; Serna C; Yu Z; Restifo NP; Rosenberg SA; Morgan RA; Hinrichs CS
    J Immunother Cancer; 2020 Jan; 8(1):. PubMed ID: 31959727
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Intratumoral administration of mRNA encoding a fusokine consisting of IFN-β and the ectodomain of the TGF-β receptor II potentiates antitumor immunity.
    Van der Jeught K; Joe PT; Bialkowski L; Heirman C; Daszkiewicz L; Liechtenstein T; Escors D; Thielemans K; Breckpot K
    Oncotarget; 2014 Oct; 5(20):10100-13. PubMed ID: 25338019
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Immunostimulatory effects of targeted thorium-227 conjugates as single agent and in combination with anti-PD-L1 therapy.
    Lejeune P; Cruciani V; Berg-Larsen A; Schlicker A; Mobergslien A; Bartnitzky L; Berndt S; Zitzmann-Kolbe S; Kamfenkel C; Stargard S; Hammer S; Jørgensen JS; Jackerott M; Nielsen CH; Schatz CA; Hennekes H; Karlsson J; Cuthbertson AS; Mumberg D; Hagemann UB
    J Immunother Cancer; 2021 Oct; 9(10):. PubMed ID: 34615703
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Localized immunotherapy via liposome-anchored Anti-CD137 + IL-2 prevents lethal toxicity and elicits local and systemic antitumor immunity.
    Kwong B; Gai SA; Elkhader J; Wittrup KD; Irvine DJ
    Cancer Res; 2013 Mar; 73(5):1547-58. PubMed ID: 23436794
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Interleukin-18 in cancer immunology and immunotherapy.
    Cirella A; Olivera I; Luri-Rey C; Bolaños E; Berraondo P; Melero I
    Expert Opin Ther Targets; 2023; 27(11):1035-1042. PubMed ID: 37993172
    [TBL] [Abstract][Full Text] [Related]  

  • 31. PD-L1 chimeric costimulatory receptor improves the efficacy of CAR-T cells for PD-L1-positive solid tumors and reduces toxicity in vivo.
    Liao Q; Mao Y; He H; Ding X; Zhang X; Xu J
    Biomark Res; 2020 Nov; 8(1):57. PubMed ID: 33292688
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Oncolytic measles virus encoding interleukin-12 mediates potent antitumor effects through T cell activation.
    Veinalde R; Grossardt C; Hartmann L; Bourgeois-Daigneault MC; Bell JC; Jäger D; von Kalle C; Ungerechts G; Engeland CE
    Oncoimmunology; 2017; 6(4):e1285992. PubMed ID: 28507792
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Nanoscale, antigen encounter-dependent, IL-12 delivery by CAR T cells plus PD-L1 blockade for cancer treatment.
    Yang Z; Pietrobon V; Bobbin M; Stefanson O; Yang J; Goswami A; Alphson B; Choi H; Magallanes K; Cai Q; Barrett D; Wang B; Qi LS; Marincola FM
    J Transl Med; 2023 Feb; 21(1):158. PubMed ID: 36855120
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Engineering of a trispecific tumor-targeted immunotherapy incorporating 4-1BB co-stimulation and PD-L1 blockade.
    Warmuth S; Gunde T; Snell D; Brock M; Weinert C; Simonin A; Hess C; Tietz J; Johansson M; Spiga FM; Heiz R; Flückiger N; Wagen S; Zeberer J; Diem D; Mahler D; Wickihalder B; Muntwiler S; Chatterjee B; Küttner B; Bommer B; Yaman Y; Lichtlen P; Urech D
    Oncoimmunology; 2021; 10(1):2004661. PubMed ID: 35844969
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Favorable alteration of tumor microenvironment by immunomodulatory cytokines for efficient T-cell therapy in solid tumors.
    Tähtinen S; Kaikkonen S; Merisalo-Soikkeli M; Grönberg-Vähä-Koskela S; Kanerva A; Parviainen S; Vähä-Koskela M; Hemminki A
    PLoS One; 2015; 10(6):e0131242. PubMed ID: 26107883
    [TBL] [Abstract][Full Text] [Related]  

  • 36. PD-L1 targeting high-affinity NK (t-haNK) cells induce direct antitumor effects and target suppressive MDSC populations.
    Fabian KP; Padget MR; Donahue RN; Solocinski K; Robbins Y; Allen CT; Lee JH; Rabizadeh S; Soon-Shiong P; Schlom J; Hodge JW
    J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32439799
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Gemcitabine-facilitated modulation of the tumor microenvironment and PD-1/PD-L1 blockade generate a synergistic antitumor effect in a murine hepatocellular carcinoma model.
    Wang H; He X; Fang D; Wang X; Guan J; Shi ZW; Chen X
    Clin Res Hepatol Gastroenterol; 2022 Apr; 46(4):101853. PubMed ID: 34923183
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Colocalized targeting of TGF-β and PD-L1 by bintrafusp alfa elicits distinct antitumor responses.
    Lan Y; Yeung TL; Huang H; Wegener AA; Saha S; Toister-Achituv M; Jenkins MH; Chiu LY; Lazorchak A; Tarcic O; Wang H; Qi J; Locke G; Kalimi D; Qin G; Marelli B; Yu H; Gross AW; Derner MG; Soloviev M; Botte M; Sircar A; Ma H; Sood VD; Zhang D; Jiang F; Lo KM
    J Immunother Cancer; 2022 Jul; 10(7):. PubMed ID: 35858707
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Immunovirotherapy with vesicular stomatitis virus and PD-L1 blockade enhances therapeutic outcome in murine acute myeloid leukemia.
    Shen W; Patnaik MM; Ruiz A; Russell SJ; Peng KW
    Blood; 2016 Mar; 127(11):1449-58. PubMed ID: 26712908
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Combination of a novel heat shock protein 90-targeted photodynamic therapy with PD-1/PD-L1 blockade induces potent systemic antitumor efficacy and abscopal effect against breast cancers.
    Kaneko K; Acharya CR; Nagata H; Yang X; Hartman ZC; Hobeika A; Hughes PF; Haystead TAJ; Morse MA; Lyerly HK; Osada T
    J Immunother Cancer; 2022 Sep; 10(9):. PubMed ID: 36171008
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.